Stockscreener 앱 받기
29.66
0.68%
0.20
전일 마감가:
$29.46
열려 있는:
$28.91
하루 거래량:
1.18M
Relative Volume:
0.55
시가총액:
$3.06B
수익:
$164.01M
순이익/손실:
$-65.04M
주가수익비율:
-43.17
EPS:
-0.687
순현금흐름:
$-383.84M
1주 성능:
+1.16%
1개월 성능:
+4.62%
6개월 성능:
+8.09%
1년 성능:
+59.98%
1일 변동 폭
$28.91
$29.97
1주일 범위
$28.02
$30.18
52주 변동 폭
$18.72
$38.26
빔 테라퓨틱스 Stock (BEAM) Company Profile
명칭
Beam Therapeutics Inc
전화
857-327-8775
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
29.66 | 2.93B | 164.01M | -65.04M | -383.84M | -0.687 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
빔 테라퓨틱스 Stock (BEAM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-20 | 개시 | Canaccord Genuity | Buy |
| 2025-10-09 | 개시 | Jefferies | Buy |
| 2025-03-28 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-03-10 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-07-23 | 개시 | H.C. Wainwright | Buy |
| 2024-01-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-12-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-10-20 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-20 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | 개시 | Citigroup | Buy |
| 2022-06-17 | 개시 | BMO Capital Markets | Market Perform |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2022-01-05 | 개시 | Guggenheim | Buy |
| 2021-10-19 | 개시 | SVB Leerink | Outperform |
| 2021-09-24 | 재개 | Stifel | Buy |
| 2021-09-10 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Redburn | Buy |
| 2021-05-04 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-02-16 | 개시 | Wells Fargo | Overweight |
| 2021-01-29 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-08-05 | 개시 | William Blair | Outperform |
| 2020-03-02 | 개시 | Barclays | Overweight |
| 2020-03-02 | 개시 | JP Morgan | Overweight |
| 2020-03-02 | 개시 | Jefferies | Buy |
| 2020-03-02 | 개시 | Wedbush | Outperform |
모두보기
빔 테라퓨틱스 주식(BEAM)의 최신 뉴스
Beam Therapeutics (NASDAQ:BEAM) Stock Price Down 6.2%Here's What Happened - MarketBeat
Beam (BEAM) Range: Posts a 1.62% Loss to $28.60 on the Day; Current Setup: $27.17 and $30.03 Define the Nearby Reference Levels in the Available RecordDebt Free Companies - Vinanet
Ultragenyx's gene therapy wins first FDA approval for rare metabolic disorder - Reuters
Beam (BEAM) Latest Quarter: EPS Falls Short of Its Estimate on the Day; Post-Earnings: The Stock Gains 9.41% in the Current UpdateRevenue Inflection Point - Vinanet
Beam (BEAM) Today: Adds 6.91% to Close at $28.41 on the Day; Range Check: Price Remains Between $26.99 Support and $29.83 Resistance in the Available RecordRVOL Spike - Vinanet
Beam Therapeutics (NASDAQ:BEAM) Shares Gap UpShould You Buy? - MarketBeat
Alphabet Inc. Purchases New Shares in Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics (BEAM) Edges Higher as Gene Editing Sector Draws Fresh AttentionCash Secured Put - Vinanet
Beam Therapeutics Inc. (NASDAQ:BEAM) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Downgraded by Wall Street Zen to "Strong Sell" - MarketBeat
Beam Therapeutics (BEAM): ARK Investment and Cathie Wood report 9.95% stake - Stock Titan
Farallon funds report 10.28M-share, 9.99% Beam Therapeutics (BEAM) position - Stock Titan
Equities Analysts Offer Predictions for BEAM Q3 Earnings - MarketBeat
Beam Therapeutics Inc (BEAM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy By Investing.com - Investing.com UK
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy - Investing.com
Analyst Forecasts Just Became More Bearish On Beam Therapeutics Inc. (NASDAQ:BEAM) - simplywall.st
Weekly Recap: H1 2026 financials and BEAM-302 pivotal cohort dosing - TradingView
Beam Therapeutics Inc. $BEAM Shares Acquired by Janus Henderson Group PLC - MarketBeat
(BEAM) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Beam Therapeutics (NASDAQ:BEAM) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Analysts Have Lowered Expectations For Beam Therapeutics Inc. (NASDAQ:BEAM) After Its Latest Results - webull.com
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80 - Moomoo
Beam Therapeutics Inc (BEAM) Stock News Today - TradingKey
First Trust Advisors LP Increases Stock Position in Beam Therapeutics Inc. $BEAM - MarketBeat
A Quick Look at Today's Ratings for Beam Therapeutics(BEAM.US), With a Forecast Between $43 to $78 - moomoo.com
RBC Capital Keeps Their Hold Rating on Beam Therapeutics (BEAM) - The Globe and Mail
BEAM News | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
Analysts Are Bullish on These Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Beam Therapeutics (BEAM) - The Globe and Mail
BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus - Yahoo Finance
Beam Therapeutics Inc. Stock 12‑Month Price Target Cut to $51.07, Implies 80% Upside - TradingView
BofA Adjusts Price Target on Beam Therapeutics to $43 From $47 - marketscreener.com
BEAM SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Beam Therapeutics completes dosing in sickle cell trial - Investing.com
Beam Therapeutics completes dosing in sickle cell trial By Investing.com - Investing.com South Africa
Beam Therapeutics (NASDAQ:BEAM) Posts Quarterly Earnings Results, Misses Estimates By $0.07 EPS - MarketBeat
Beam Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Beam Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Beam Therapeutics Inc. 2Q 2026: Revenue $0.5M, EPS $(1.18) — 10-Q Summary - TradingView
Beam Therapeutics Reports Q2 2026 Results and Clinical Updates for BEAM-302, Risto-cel and BEAM-304 - Quiver Quantitative
Beam Therapeutics (Nasdaq: BEAM) holds $1.2B cash, plans risto-cel BLA - Stock Titan
Beam Therapeutics reports Q2 2026 results: $1.15B cash, $122.7M net loss - TradingView
Beam Therapeutics (NASDAQ: BEAM) details Q2 loss, $1.2B cash and pipeline plans - Stock Titan
Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) - marketscreener.com
Beam expects $1.2B cash plus $200M draw to fund plans into mid-2029 - Stock Titan
Beam Therapeutics Inc. (BEAM) Stock Analysis: A Potential 101.88% Upside in the Biotech Arena - DirectorsTalk Interviews
Beam Therapeutics: A Valuation With Upside Left (NASDAQ:BEAM) - Seeking Alpha
Dimensional Fund Advisors LP Has $51.33 Million Stock Position in Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Renaissance Technologies LLC Boosts Stake in Beam Therapeutics Inc. $BEAM - MarketBeat
빔 테라퓨틱스 (BEAM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.86%
0.31%
자본화:
|
볼륨(24시간):